首页 | 本学科首页   官方微博 | 高级检索  
     

五味子甲素协同吉西他滨抑制肝癌细胞HepG2增殖
引用本文:薛燕,曾智锐,雷珊,孙远梅,兰金芝,张金娟,杨宇石,徐澍,陈腾祥. 五味子甲素协同吉西他滨抑制肝癌细胞HepG2增殖[J]. 中国药理学通报, 2020, 0(4): 550-555
作者姓名:薛燕  曾智锐  雷珊  孙远梅  兰金芝  张金娟  杨宇石  徐澍  陈腾祥
作者单位:贵州医科大学基础医学院生理学教研室;贵州省再生医学重点实验室;基础医学院机能实验室;临床医学院病理学教研室
基金项目:贵州省科技厅贵州省应用基础研究计划重大专项(黔科合J重大字[2015]2003);筑科合同[2017]5-11号。
摘    要:目的探究五味子甲素(deoxyschizandrin)联合吉西他滨(gemcitabin,GEM)对肝癌细胞HepG2增殖的影响及其可能的作用机制。方法CCK8法和克隆平板实验检测五味子甲素单药、GEM单药及联合用药对肝癌细胞HepG2增殖能力的影响;流式细胞术检测单药组及联合用药组中HepG2细胞的凋亡比例;Western blot法检测各组细胞中BCL2、BAX、pro-caspase3、cleaved-caspase3、pro-caspase9、cleaved-caspase9、β-catenin和TCF-4的表达。结果五味子甲素、GEM及联合用药对细胞HepG2的增殖均具有抑制作用,促进其凋亡,且联合用药组对HepG2细胞的作用明显强于单药组(P<0.05);Western blot结果表明,与对照组相比,五味子甲素、GEM和联合用药对pro-caspase3、pro-caspase9表达无明显影响,显著减少BCL2、β-catenin及TCF-4蛋白的表达(P<0.05),上调BAX、cleaved-caspase3、cleaved-caspase9蛋白的表达(P<0.05)。其中,联合用药比单药更为显著(P<0.05)。结论五味子甲素协同GEM抑制肝癌细胞HepG2中β-catenin/TCF-4通路,进而减少细胞增殖,诱导其凋亡。

关 键 词:五味子甲素  吉西他滨  肝癌  HEPG2  增殖  凋亡  β-catenin/TCF4通路

Synergy effect of deoxyschizandrin and gemcitabine on proliferation of HepG2 human hepatocellular carcinoma cells
XUE Yan,ZENG Zhi-rui,LEI Shan,SUN Yuan-mei,LAN Jin-zhi,ZHANG Jin-juan,YANG Yu-shi,XU Shu,CHEN Teng-xiang. Synergy effect of deoxyschizandrin and gemcitabine on proliferation of HepG2 human hepatocellular carcinoma cells[J]. Chinese Pharmacological Bulletin, 2020, 0(4): 550-555
Authors:XUE Yan  ZENG Zhi-rui  LEI Shan  SUN Yuan-mei  LAN Jin-zhi  ZHANG Jin-juan  YANG Yu-shi  XU Shu  CHEN Teng-xiang
Affiliation:(Dept of Physiology,School of Basic Medical Science,Guizhou Provincial Key Lab of Pathogenesis&Drug Research on Common Chronic Diseases;Dept of Pathology,Guizhou Medical University;Dept of Regenerate Research;Lab of Functional Experiments,Guiyang 550004,China)
Abstract:Aim To investigate the synergy effects of deoxyschizandrin and gemcitabine(GEM)on the proliferation of HepG2 human hepatocellular carcinoma cells in vitro and the underlying mechanism.Methods CCK8 method and colony formation assay were used to detect the effects of deoxyschizandrin monotherapy,GEM monotherapy and combination therapy on the proliferation of HepG2 cells.Flow cytometry was used to detect the change of apoptosis rate of HepG2 cells after treatment with single drug or the combination use of two drugs.Western blot was performed to detect the expression of BCL2,BAX,pro-caspase3,caspase3,pro-caspase9,caspase9,β-catenin and TCF-4.Results Deoxyschizandrin,GEM and combination group significantly inhibited the proliferation of HepG2 cells and promoted cell apoptosis.The effects of the combination group on HepG2 cells were significantly stronger than those of single-drug groups(P<0.05).Western blot results showed the expression of pro-caspase3 and pro-caspase9 was changed slightly within deoxyschizandrin,GEM and combination groups compared with that of normal control,while the expression of BCL2,β-catenin and TCF-4 protein expression was down-regulated significantly(P<0.05).The expression of BAX,cleaved-caspase3 and cleaved-caspase 9 protein increased significantly after treatment with deoxyschizandrin,GEM and combination group(P<0.05).Specially,the increasing effect of the expression of the protein in combined group was more significant than that of single drug groups(P<0.05).Conclusions The combination of deoxyschizandrin and GEM significantly inhibited the proliferation of HepG2 cells and induced cell apoptosis,as well as suppressed theβ-catenin/TCF-4 pathway.
Keywords:deoxyschizandrin  gemcitabine  human hepatocellular carcinoma  HepG2  proliferation  apoptosis  β-catenin/TCF-4 pathway
本文献已被 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号